CVE-2026-76237
Cross-tenant authorization flaw in stigmem-node multi-tenant plugin.
Is CVE-2026-76237 being exploited?
Not confirmed. CVE-2026-76237 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.29% probability of exploitation in the next 30 days.
How severe is CVE-2026-76237?
CVE-2026-76237 is rated High with a CVSS score of 8.6. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-76237?
Yes. A fix has been recorded for CVE-2026-76237. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-76237 affect?
CVE-2026-76237 affects stigmem-node < 0.9.0a12 with stigmem-plugin-multi-tenant, Multi-tenant deployments using stigmem-plugin-multi-tenant. Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-76237?
Upgrade stigmem-node to >=0.9.0a12 or disable the multi-tenant plugin; audit tenant privileges.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Tenant admin can list/read/admit/reject other tenants' quarantined facts via /v1/quarantine (cross-tenant BOLA).
Immediate action required
- affected< 0.9.0a12
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.